MedTrace Logo

Drug Use Investigation of COMIRNATY Intramuscular Injection

NCT04815031 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14570

Last updated 2024-11-27

Study results available
· View outcomes & findings →

Summary

Post-marketing study, Chotor study of COMIRNATY vaccenees followed for 11months. Serious adverse events and COVID-19 observed during the follow-up period will be collected, and the long-term safety of this product will be assessed.

Conditions

Interventions

BIOLOGICAL

BNT162b2

Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-20
Primary Completion
2023-01-27
Completion
2023-01-27

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04815031 on ClinicalTrials.gov